NCT03603678View on ClinicalTrials.gov

Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

May 23, 2019

Study Completion Date

September 2, 2019

Conditions
Sleep Apnea, Obstructive
Interventions
DRUG

BAY2253651

100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally

DRUG

Placebo

Matching Placebo dosing

Trial Locations (2)

8091

University Hospital Zürich, Zurich

OX9 3DU

Oxford University Hospitals, Oxford

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY